Share on StockTwits

NuVasive (NASDAQ:NUVA) EVP Russell Powers sold 3,200 shares of NuVasive stock on the open market in a transaction dated Thursday, July 10th. The stock was sold at an average price of $33.43, for a total value of $106,976.00. Following the transaction, the executive vice president now directly owns 42,984 shares of the company’s stock, valued at approximately $1,436,955. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

NuVasive (NASDAQ:NUVA) traded up 0.73% during mid-day trading on Friday, hitting $35.68. The stock had a trading volume of 245,084 shares. NuVasive has a one year low of $22.44 and a one year high of $39.89. The stock’s 50-day moving average is $34.34 and its 200-day moving average is $35.33. The company’s market cap is $1.663 billion.

NuVasive (NASDAQ:NUVA) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.29 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.23 by $0.06. The company had revenue of $177.50 million for the quarter, compared to the consensus estimate of $171.30 million. During the same quarter in the prior year, the company posted $0.26 earnings per share. The company’s quarterly revenue was up 11.3% on a year-over-year basis. On average, analysts predict that NuVasive will post $1.09 earnings per share for the current fiscal year.

NUVA has been the subject of a number of recent research reports. Analysts at Goldman Sachs upgraded shares of NuVasive from a “neutral” rating to a “buy” rating in a research note on Wednesday, June 25th. Separately, analysts at Needham & Company LLC downgraded shares of NuVasive from a “buy” rating to a “hold” rating in a research note on Wednesday, May 21st. They now have a $40.00 price target on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of NuVasive from $51.00 to $48.00 in a research note on Wednesday, April 30th. They now have a “buy” rating on the stock. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $39.26.

NuVasive, Inc is a medical device company, that focuses on developing minimally disruptive surgical products and procedures for the spine.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.